# Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

> **NCT01048034** · PHASE2 · COMPLETED · sponsor: **Nordic MDS Group** · enrollment: 30 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Erythropoetin

## Key facts

- **NCT ID:** NCT01048034
- **Lead sponsor:** Nordic MDS Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01048034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01048034, "Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01048034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*